 |
Technical Data |
|
C2392-31H |
CD40 Ligand, Soluble, Recombinant, Human (CD40L, CD40-L, hCD40L, CD40LG, CD154, gp39, HIGM1, IGM, IMD3, T-BAM, T-cell Antigen Gp39, TNF-related Activation Protein, TRAP, Tumor Necrosis Factor Ligand Superfamily Member 5, TNFSF5) |
10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 149aa of human soluble CD40(CD154) Ligand/TRAP expressed in E.coli is a non-glycosylated, polypeptide chain. Molecular Weight: ~16.3kD Biological Activity: The ED50 as determined by the dose-dependent stimulation of IL-12 & IL-8 induction by PMB (Peripheral Mononuclear) cells was found to be 5-10nug/ml. Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods:1. UV spectroscopy at 280nm using the absorbency value of 1.1 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of soluble CD40L as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~16.3kD |
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: ~1mg/ml Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
|
1. Targeting LFA-1 and CD154 Suppresses the In Vivo Activation and Development of Cytolytic (CD4-Independent) CD8+ T Cells. J Immunol 2005 Dec 15;175(12):7855-7866. 2. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-{gamma}- and CD40L-mediated costimulation. J Leukoc Biol 2005 Dec 5; 3. The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats. Mol Cell Biochem 2006 Jan;282(1-2):141-6. 4. Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction. Immunology 2005 Dec;116(4):454-63. 5. Evidence for the requirement for CD40-CD154 interactions in resistance to infections with attenuated Salmonella. J Endotoxin Res 2005;11(6):395-9. 6. Preferential Th2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int Immunol 2005 Dec;17(12):1619-29.
|
||